Trials / Active Not Recruiting
Active Not RecruitingNCT06196827
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
A Multi-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of rAAV2-RPE65 Gene Therapy (LX101) in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX101 | Subretinal Administration |
Timeline
- Start date
- 2022-07-02
- Primary completion
- 2023-12-06
- Completion
- 2027-12-01
- First posted
- 2024-01-09
- Last updated
- 2026-03-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06196827. Inclusion in this directory is not an endorsement.